The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion
Official Title: Registry for Molecular Testing, Treatment and Outcome of Patients With Locally Advanced or Metastatic Solid Tumors Harboring a Fusion of NTRK1, NTRK2 or NTRK3
Study ID: NCT04557813
Brief Summary: The objective of this registry is to analyze treatment reality and outcome of patients with locally advanced or metastatic solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3
Detailed Description: The REALTRK registry will provide data on treatment reality of patients with locally advanced or metastatic solid tumors harboring NTRK1, NTRK2 or NTRK3 gene fusions, thereby generating real world evidence. It will identify factors that influence treatment decisions after receiving the diagnosis of a NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive cancer. All treatment lines administered before and after the molecular diagnosis of a NTRK fusion-positive cancer, irrespective of the type of antineoplastic treatment, will be documented. Data will be assessed at least 36 months per patient (i.e. until 36 months after inclusion of the last patient in the study). This approach will allow a description of TRK fusion protein-targeted therapies and other therapy strategies regarding effectiveness and disease-related symptomology within the limitations of non-randomized studies in terms of comparative analyses. Intra-individual and inter-individual comparisons (for the latter, provided that a sufficient number of patients with a NTRK fusion-positive cancer are not treated with a TRK inhibitor) could be performed. The associated biomarker profiling module of the REALTRK registry will aim to set up a decentralized biobank for future research on molecular alterations.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Onkologische Schwerpunktpraxis KurfĂźrstendamm, Berlin, , Germany
Centrum fßr Hämatologie und Onkologie Bethanien, Frankfurt, , Germany
Praxis fßr interdisziplinäre Onkologie & Hämatologie, Freiburg, , Germany
Asklepios Klinik Altona, Hamburg, , Germany
Onkologische Schwerpunktpraxis, Hannover, , Germany
Gemeinschaftspraxis, Hannover, , Germany
SLK Kliniken Heilbronn Klinik fĂźr Innere Medizin III, Heilbronn, , Germany
Klinikum Kempten, Kempten, , Germany
PIOH - Praxis Internistische Onkologie und Hämatologie, KÜln, , Germany
Asklepios MVZ Bayern, Schwerpunkt Hämatologie/Onkologie, Landsberg, , Germany
Onkologische Praxis am Marien-Krankenhaus, LĂźbeck, , Germany
Praxis fĂźr Onkologie, MĂśnchengladbach, , Germany
Klinikum rechts der Isar der TUM Innere Medizin II, MĂźnchen, , Germany
Universitätsklinikum Mßnster, Medizinische Klinik A, Mßnster, , Germany
TZN - Tumorzentrum Niederrhein GmbH, Neuss, , Germany
Studienzentrum Onkologie Ravensburg, Ravensburg, , Germany
Praxis und Tagesklinik fßr Onkologie und Hämatologie, Recklinghausen, , Germany
Klinikum Rosenheim, Rosenheim, , Germany
Zentrum Ambulante Onkologie, Schorndorf, , Germany
MVZ Kloster Paradiese GbR, Soest, , Germany
MVZ fßr Hämatologie und Onkologie, Ulm, , Germany
Onkologie Schwarzwald-Alb, Villingen-Schwenningen, , Germany
Universitätsspital Basel, Basel, , Switzerland
Name: Benjamin Kasenda, PD Dr. Dr.
Affiliation: Universitätsspital Basel, Petersgraben 4, 4031 Basel, Switzerland
Role: STUDY_DIRECTOR